2. Search Result
Search Result
Results for "

diacylglycerol acyltransferase 2

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108341A
    PF-06424439 methanesulfonate
    20+ Cited Publications

    		 Acyltransferase Metabolic Disease
    PF-06424439 methanesulfonate is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 methanesulfonate is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
    PF-06424439 methanesulfonate
  • HY-108341
    PF-06424439
    20+ Cited Publications

    		 Acyltransferase Metabolic Disease
    PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
    PF-06424439
  • HY-169499
    (R)-2-(3-(2-Ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxylic Acid

    		Acyltransferase Metabolic Disease
    (R)-2-(3-(2-Ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxylic Acid is an intermediate in the synthesis of the diacylglycerol acyltransferase 2 (DGAT-2) inhibitor Ervogastat.
    (R)-2-(3-(2-Ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxylic Acid
  • HY-110381
    JNJ-DGAT2-A

    		Acyltransferase Metabolic Disease
    JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis .
    JNJ-DGAT2-A
  • HY-145624
    Obeversen

    ION-769357

    		 Acyltransferase Metabolic Disease
    Obeversen is an antisense oligonucleotide that inhibits the synthesis of diacylglycerol acyltransferase 2 (DGAT-2). Obeversen can be used in the research of nonalcoholic fatty liver disease .
    Obeversen
  • HY-138942
    PF-06427878

    		Acyltransferase Metabolic Disease Inflammation/Immunology
    PF-06427878 is an orally active, selective liver-targeted diacylglycerol acyltransferase 2 (DGAT2) inhibitor with IC50s of 99 nM and 202 nM for human and rat DGAT2, respectively. PF-06427878 shows greater than 470-fold selectivity for DGAT2 over DGAT1, MGAT1, MGAT2 and MGAT3. PF-06427878 can improve liver steatosis and function. PF-06427878 can be used for the study of nonalcoholic fatty liver diseases .
    PF-06427878
  • HY-145624A
    Obeversen sodium

    ION-769357 sodium

    		 Acyltransferase Metabolic Disease
    Obeversen sodium is an antisense oligonucleotide that inhibits the synthesis of Diacylglycerol acyltransferase 2 (DGAT-2). Obeversen sodium can be used in the research of nonalcoholic fatty liver disease .
    Obeversen sodium
  • HY-108341R
    PF-06424439 (Standard)

    		Reference Standards Acyltransferase Metabolic Disease
    PF-06424439 (Standard) is the analytical standard of PF-06424439 (HY-108341). This product is intended for research and analytical applications. PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
    PF-06424439 (Standard)
  • HY-108341AR
    PF-06424439 methanesulfonate (Standard)

    		Reference Standards Acyltransferase Metabolic Disease
    PF-06424439 methanesulfonate (Standard) is the analytical standard of PF-06424439 (methanesulfonate) (HY-108341A). This product is intended for research and analytical applications. PF-06424439 methanesulfonate is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 methanesulfonate is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
    PF-06424439 methanesulfonate (Standard)
  • HY-118386
    H2-005

    		Endogenous Metabolite Metabolic Disease
    H2-005 is a compound that selectively inhibits diacylglycerol acyltransferase 2 (DGAT2) and has the activity to inhibit triacylglycerol synthesis in hepatocytes and preadipocytes. H2-005 significantly reduces triacylglycerol biosynthesis in HepG2 hepatocytes and 3T3-L1 preadipocytes. H2-005 exhibits specific inhibitory activity in DGAT2-overexpressing HEK293 cells. H2-005 almost completely inhibits lipid droplet formation in 3T3-L1 cells when co-treated with a DGAT1 inhibitor. H2-005 will contribute to DGAT2-related lipid metabolism research and the development of drugs to inhibit metabolic diseases .
    H2-005

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: